SkinBioTherapeutics plc (LON:SBTX – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as GBX 19.74 ($0.25) and last traded at GBX 18.99 ($0.24), with a volume of 1687400 shares traded. The stock had previously closed at GBX 18.90 ($0.24).
SkinBioTherapeutics Trading Down 7.9 %
The company’s 50-day moving average is GBX 15.59 and its 200 day moving average is GBX 12.60. The company has a current ratio of 6.57, a quick ratio of 10.01 and a debt-to-equity ratio of 2.66. The firm has a market cap of £39.57 million, a PE ratio of -873.75 and a beta of 2.01.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
Recommended Stories
- Five stocks we like better than SkinBioTherapeutics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
